{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-118586","form_type":"8-K","ticker":"LRMR","cik":"0001374690","company_name":"Larimar Therapeutics, Inc.","filed_at":"2024-10-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.284142+00:00","generated_at":"2026-05-30T08:08:25.019767+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Larimar reports Q3 2024 net loss of $15.5M; cash $203.7M, BLA target 2H 2025","bullets":["Net loss of $15.5M ($0.24 per share) vs $9.1M loss ($0.21 per share) in Q3 2023.","Cash, cash equivalents and marketable securities $203.7M as of Sep 30, 2024; projected runway into 2026.","Nomlabofusp program update in mid-Dec with safety, PK, frataxin data from 25 mg daily OLE study.","PK run-in study in adolescents on track by year-end 2024; global confirmatory study planned mid-2025.","BLA submission for nomlabofusp targeted for 2H 2025 to support potential accelerated approval."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-118586","json":"https://secwatch.observer/filing/0000950170-24-118586.json","markdown":"https://secwatch.observer/filing/0000950170-24-118586.md","text":"https://secwatch.observer/filing/0000950170-24-118586.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024118586/0000950170-24-118586-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374690/000095017024118586/lrmr-20241030.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T08:08:25.019767+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}